Kairos Pharma Ltd. (NYSE American: KAPA) has reported encouraging interim safety results from its ongoing Phase 2 trial of ENV-105 (carotuximab) in patients with metastatic castration-resistant prostate cancer. The study, involving the first ten patients, revealed no dose-limiting toxicities or unexpected adverse events, with ENV-105 being well tolerated in combination with apalutamide, a standard hormone therapy. This development is crucial as it underscores the potential of ENV-105, a first-in-class CD105 antagonist, to offer a safer treatment option for a challenging form of prostate cancer.
The trial, which is currently enrolling 100 patients across prestigious institutions like Cedars-Sinai, City of Hope, and Huntsman Cancer Center, is expected to release interim efficacy data by September 2025. The positive safety profile observed so far paves the way for Kairos Pharma to engage with regulators regarding a potential Phase 3 study, highlighting the drug's promise in addressing significant unmet medical needs in oncology.
ENV-105 targets CD105, a protein implicated in resistance to various cancer treatments, aiming to reverse drug resistance and enhance the effectiveness of standard therapies. This approach could revolutionize treatment strategies not only for prostate cancer but potentially for other cancer types where CD105 plays a role in disease progression and resistance. For more information on the trial and Kairos Pharma's innovative research, visit https://www.KairosPharma.com.
